Digitoxin as a novel synergistic partner of cisplatin in triple-negative breast cancer (TNBC) cells
{{output}}
BackgroundTriple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive nature, high recurrence rate, and lack of targeted therapies. To address these limitations, combination chemotherapies that synergistically enhance antitumor ef... ...
